MEDVi review

MEDVi sells access to GLP-1 treatment through independent clinicians and pharmacy partners. Its tirz-166 landing page advertises semaglutide injections at $116 a month and tirzepatide at $166, with price-lock language. Those figures belong to that offer: the required purchase term, upfront total and state restrictions were not established. A low monthly equivalent can still mean a larger initial payment.

FDA issued warning letter 721455 to MEDVi, LLC dba MEDVi on February 20, 2026, following its review of medvi.io in December 2025. The agency cited labeling that suggested MEDVi compounded the medication and marketing that implied FDA evaluation of compounded semaglutide and tirzepatide.

The letter names 131 Continental Drive, Suite 305, Newark, Delaware; the current home.medvi.org site lists the same address. This is relevant dated regulatory context, not a finding about every later offer. The source check did not establish whether FDA subsequently accepted corrective action or issued a closeout.

The same offer lists Wegovy pill, Wegovy injection and Zepbound injection with a $99 membership charge plus medication. That is not a $99 prescription. The dissolvable-tablet card had an unresolved price variable, so it cannot support a reliable oral-compound quote. Ask for the exact medication, formulation and total before choosing a route.

MEDVi names CareGLP Affiliated P.C.s/OpenLoop and pharmacy partners including TriadRx, Red Rock and Beaker on its public site. These names give you something concrete to check; they do not identify which clinician or pharmacy will handle your own prescription.

The cancellation policy requests 72 hours of notice before billing. It also contains early-cancellation and unshipped multi-month refund language alongside a medical-disqualification-only restriction. Get written clarification for your selected plan before relying on a refund. This is especially important when committing to several months in advance.